Blay JY, Le Cesne A, Ray-Coquard I, et al: Prospective multicentric randomized phase III study of imatinib(Drug information on imatinib) in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: The French Sarcoma Group. J Clin Oncol 25:1107–1113, 2007.
Cherix S, Speiser M, Matter M, et al: Isolated limb perfusion with tumor necrosis factor and melphalan(Drug information on melphalan) for non-resectable soft tissue sarcomas: Long-term results on efficacy and limb salvage in a selected group of patients. J Surg Oncol 98:148–155, 2008.
Choi H, Charnsangavej C, Faria SC, et al: Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria. J Clin Oncol 25:1753–1759, 2007.
Chugh R, Wathen JK, Maki RG, et al: Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model. J Clin Oncol 27:3148–3153, 2009.
Corless CL, Fletcher JA, Heinrich MC, et al: Biology of gastrointestinal stromal tumors. J Clin Oncol 22:3813–3825, 2004.
Corless CL, Ballman CV, Antonescu C, et al: Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): Results of the intergroup phase III trial ACOSOG Z9001. J Clin Oncol 28(suppl 15s): abstract 10006, 2010.
Cormier JN, Huang X, Xing Y, et al: Cohort analysis of patients with localized, high-risk, extremity soft tissue sarcoma treated at two cancer centers: Chemotherapy-associated outcomes. J Clin Oncol 22:4567–4574, 2004.
Davis A, O'Sullivan B, Turcotte R, et al: Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma. Radiother Oncol 75:48-53, 2005.
DeLaney TF, Spiro IJ, Suit HD, et al: Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas. Int J Radiat Oncol Biol Phys 56:1117–1127, 2003.
DeMatteo RP, Ballman KV, Antonescu CR, et al: Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 373:1097–1104, 2009.
Demetri GD, van Oosterom AT, Garrett CR, et al: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 368:1329–1338, 2006.
Dileo P, Morgan JA, Zahrieh D, et al: Gemcitabine(Drug information on gemcitabine) and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: Results of a phase II trial. Cancer 109:1863–1869, 2007.
Eggermont AM, Schraffordt Koops H, Klausner JM, et al: Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas: The cumulative multicenter European experience. Ann Surg 224:756–764, 1996.
Eilber FC, Eilber FR, Eckardt J, et al: The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma. Ann Surg 240:686–695, 2004.
Eilber FC, Rosen G, Nelson SD, et al: High-grade extremity soft-tissue sarcomas: Factors predictive of local recurrence and its effect on morbidity and mortality. Ann Surg 237:218–226, 2003.
Feng M, Murphy J, Griffith KA, et al: Long-term outcomes after radiotherapy for retroperitoneal and deep truncal sarcoma. Int J Radiat Oncol Biol Phys 69:103–110, 2007.
Ferrari A, Gronchi A, Casanova M, et al: Synovial sarcoma: A retrospective analysis of 271 patients of all ages treated at a single institution. Cancer 101:627–634, 2004.
Frustaci S, De Paoli A, Bidoli E, et al: Ifosfamide(Drug information on ifosfamide) in the adjuvant therapy of soft tissue sarcomas. Oncology 65(suppl 2):80–84, 2003.
Heinrich MC, Corless CL, Blanke CD, et al: Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 24:4764–4774, 2006.
Heinrich MC, Maki RG, Corless CL, et al: Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 26:5352–5359, 2008.
Hensley ML, Wathen K, Maki RG, et al: Adjuvant treatment of high-risk primary uterine leiomyosarcoma with gemcitabine/docetaxel, followed by doxorubicin(Drug information on doxorubicin): Results of phase II multicenter trial SARC005. J Clin Oncol 28(15s): abstract 10021, 2010.
Joensuu H, Eriksson M, Hatrmann J, et al: Twelve versus 36 months of adjuvant imatinib as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO). J Clin Oncol 29(suppl): abstract LBA1, 2011.
Kraybill WG, Harris J, Spiro IJ, et al: Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514. J Clin Oncol 24:619–625, 2006.
Ladenstein R, Potschger U, Le Deley MC, et al: Primary disseminated multifocal Ewing Sarcoma: Results of the Euro-EWING 99 trial. J Clin Oncol 28:3284–3291, 2010.
Le Cesne A, Blay JY, Judson I, et al: Phase II study of ET-743 in advanced soft tissue sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol 23:576–584, 2005.
Maki RG, D'Adamo DR, Keohan ML, et al: Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 27:3133–3140, 2009.
O'Sullivan B, Bell RS, Bramwell VHC: Sarcomas of the soft tissues, in Souhami RL, Tannock I, Hohenberger P, et al (eds): Oxford Textbook of Oncology, 2nd ed, pp 2495–2523. Oxford, Oxford University Press, 2002.
O'Sullivan B, Davis AM, Turcotte R, et al: Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: A randomized trial. Lancet 359:2235–2241, 2002.
Pervaiz N, Colterjohn N, Farrokhyar F, et al: A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer 113:573–581, 2008.
Pisters PW, Patel SR, Prieto VG, et al: Phase I trial of preoperative doxorubicin-based concurrent chemoradiation and surgical resection for localized extremity and body wall soft tissue sarcomas. J Clin Oncol 22:3375–3380, 2004.
Pisters PW, Pollock RE, Lewis VO, et al: Long-term results of prospective trial of selective use of radiation for patients with T1 extremity and trunk soft tissue sarcomas. Ann Surg 246:675–682, 2007.
Riad S, Griffin AM, Liberman B, et al: Lymph node metastasis in soft tissue sarcoma in an extremity. Clin Orthop Sep:129–134, 2004.
van der Graaf WT, Blay JY, Chawla SP, et al: Pazopanib for metastatic soft-tissue sarcoma (PALETTE): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379:1879–1886, 2012.
Verma S, Younus J, Stys-Norman D, et al: Meta-analysis of ifosfamide-based combination chemotherapy in advanced soft tissue sarcoma. Cancer Treat Rev 34:339–347, 2008.
Wendtner C-M, Abdel-Rahman S, Krych M, et al: Response to neoadjuvant chemotherapy combined with regional hyperthermia predicts long-term survival for adult patients with retroperitoneal and visceral high-risk soft-tissue sarcomas. J Clin Oncol 20:3156–3164, 2002.
Zalcberg JR, Verweij J, Casali PG, et al: Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 41:1751–1757, 2005.